triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
=== Side-effects === Although patients at high risk of bleeding were excluded from the phase III clinical study (PROWESS), 25% of patients treated with drotrecogin and 18% of those receiving placebo experienced at least one bleeding event (principally ecchymoses or GI bleeding) during the 28-day study period. During treatment, serious bleeding events (e.g., intracranial hemorrhage, any life-threatening bleeding event, any bleeding event requiring administration of at least 3 units of packed red blood cells daily for 2 consecutive days) occurred in 2.4% of patients treated with drotrecogin and in 1% of those receiving placebo. No significant differences between geriatric patients and younger patients regarding bleeding events in the drotrecogin group were found. No non-bleeding side-effects were observed. A second study, encompassing approximately 1700 adult patients, was completed in 2011 and showed a comparable side-effect profile.
=== Notes === "Inglorious Bastards" features uncredited vocals from DJ Clue. "M.T.B.T.T.F." stands for "Mike Tyson Blow to the Face". Due to sample clearance issues with "So Be It", a "Pt. II" remix with a different instrumental was uploaded onto streaming platforms in its place upon the album's release. A few hours later, the issue would be resolved, with the original track being reinstated. The initial Kaws and Verdy physical versions of the album did not include either version of "So Be It" or Tyler, the Creator's appearance on "P.O.V.".
Its half-life must be long enough so that it will release energy at a relatively constant rate for a reasonable amount of time. The amount of energy released per time (power) of a given quantity is inversely proportional to half-life. An isotope with twice the half-life and the same energy per decay will release power at half the rate per mole. Typical half-lives for radioisotopes used in RTGs are therefore several decades, although isotopes with shorter half-lives could be used for specialized applications. For spaceflight use, the fuel must produce a large amount of power per mass and volume (density). Density and weight are not as important for terrestrial use, unless there are size restrictions. The decay energy can be calculated if the energy of radioactive radiation or the mass loss before and after radioactive decay is known. Energy release per decay is proportional to power production per mole. Radiation must be of a type easily absorbed and transformed into thermal radiation, preferably alpha radiation. Beta radiation can emit considerable gamma/X-ray radiation through bremsstrahlung secondary radiation production and therefore requires heavy shielding. Isotopes must not produce significant amounts of gamma, neutron radiation or penetrating radiation in general through other decay modes or decay chain products. The first two criteria limit the number of possible fuels to fewer than thirty nuclides within the entire table of nuclides.
== See also == Organic food Genetically modified food controversies JECFA Genetically modified organisms Dispute settlement in the WTO Pink slime The World According to Monsanto - a documentary about Monsanto's corporate practices
FC Lokomotive Leipzig was promoted to Regionalliga Nordost after finishing Oberliga sixth due to the reserve teams of FC Rot-Weiß Erfurt, Dynamo Dresden, and FC Carl Zeiss Jena being ineligible for promotion. Lokomotive finished in tenth place in the 2012–13 season but were relegated to Oberliga Nordost after finishing 15th in 2013–14. The club stayed in contention for promotion back up to the Regionalliga during the 2014–15 season, having hired former German international Mario Basler as director of sports in early 2015. In the final match of the season, Lok supporters stormed the field after their club had fallen behind 2–0, forcing the match to be abandoned and the club to finish outside of the promotion ranks. The club finished in first place in the southern group of the NOFV-Oberliga and returned to the Regionalliga Nordost for the 2016–17 season.
Sources: en.wikipedia.org
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of World Fisheries and Aquaculture 2026, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from The State of World Fisheries and Aquaculture 2024, p.10, FAO.
== External links == Major+Histocompatibility+Complex at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Molecular Individuality Archived 2013-01-29 at the Wayback Machine—German online book (2012) NetMHC 3.0 server—predicts binding of peptides to a number of different MHC (HLA) alleles T-cell Group—Cardiff University The story of 2YF6: A Chicken MHC[link removed] RCSB Protein Data Bank: Molecule of the Month—Major Histocompatibility Complex dbMHC Home, NCBI's database of the Major Histocompatibility Complex
The maturation and size of the breasts can be measured by a variety of different methods. These include Tanner staging, bra cup size, breast volume, breast–chest difference, the breast unit, breast hemicircumference, and breast circumference, among other measures.
Supercritical fluid extraction has been used in determining hydrocarbon components in water. Processes that use sCO2 to produce micro and nano scale particles, often for pharmaceutical uses, are under development. The gas antisolvent process, rapid expansion of supercritical solutions, and supercritical antisolvent precipitation (as well as several related methods) process a variety of substances into particles. Due to its ability to selectively dissolve organic compounds and assist enzyme functioning, sCO2 has been suggested as a potential solvent to support biological activity on Venus- or super-Earth-type planets.
Sources: en.wikipedia.org
== Career and research == Dai graduated from King's College London, where he also obtained his PhD. After postdoctoral work at McMaster University, Hamilton, he moved to University of Wales Cardiff, where he progressed to a personal chair. In 1989 he moved to Swansea as Head of the Mass Spectrometry Research Unit at University of Wales, Swansea. Although best known as a mass spectrometrist and separation scientist who was the first person to bring liquid chromatography-mass spectrometry to Europe, he has made considerable contributions in organic chemistry research and served as Head of the Chemistry Department at Swansea.
Similarly to the SIR model, also, in this case, we have a Disease-Free-Equilibrium (N,0,0,0) and an Endemic Equilibrium EE, and one can show that, independently from biologically meaningful initial conditions
=== December === 1 December: Prime Minister Christopher Luxon and Local Government Minister Simon Watts announce that the Government will introduce legislation to limit annual rates increases by local governments will be limited to between 2 and 4% The Professional Association for Transgender Health Aotearoa (PATHA) files a legal injunction to stop the incoming ban on new puberty blocker prescriptions, which is expected to come into force on 19 December. 3 December: A tornado causes power outages to 200 properties in the Manawatū-Whanganui region and damages several caravans at a Lake Dudding motor camp, wounding one person. Five new cases of measles are confirmed, bringing the total number of cases nationwide in the 2025 outbreak to 27. 4 December: Woolworths admits to one charge of violating the Food Act 2014 in relation to a rodent infestation at its South Dunedin store in February 2024. Former Te Pāti Māori MP Mariameno Kapa-Kingi files an interim injunction at the Wellington High Court challenging her expulsion from the party. The Post Primary Teachers' Association agrees to accept the Government's pay offer providing two pay rises totalling 4.6 percent over the next two years. Swedish multinational furniture retailer IKEA opens its first New Zealand store in Mount Wellington, Auckland. Thousands including Prime Minister Christopher Luxon attend the opening ceremony. 5 December: Member of Parliament Mariameno Kapa-Kingi is reinstated as a member of Te Pāti Māori by an interim Wellington High Court ruling.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.